Navigation Links
caprotec bioanalytics Increases Series B Financing in Second Closing to EUR 5 Million
Date:5/9/2011

BERLIN and BURLINGTON, Mass., May 9, 2011 /PRNewswire/ -- caprotec bioanalytics GmbH, a privately held biopharmaceutical company offering the proprietary Capture Compound Mass Spectrometry (CCMS) platform technology for the analysis of small molecule – protein interactions, today announced a second closing of EUR 1 million ($1.4 M) to its Series B financing, increasing total equity for the round to EUR 5 million ($7.2 M). The capital increase was fully subscribed by LBBW Venture Capital GmbH, Stuttgart, joining existing investors Creathor Venture, IBB Beteiligungsgesellschaft, ERP Startfonds, and well-known private investors.

Prof. Dr. Hubert Koster, CEO of caprotec bioanalytics GmbH, commented, "This additional funding from LBBW Venture will allow us to further leverage caprotec's CCMS technology into additional markets as diagnostics and will put the company in a position to execute several large pharma partnerships at the same time."

Dr. Harald Poth, Senior Investment Manager of LBBW Venture, added, "caprotec's CCMS technology has the potential to solve the most expensive problem in the pharmaceutical industry, the failure of drug candidates in clinical trials due to off-target interactions. With caprotec's functional proteomics platform it is possible to profile small molecule drug – protein interactions, including membrane proteins in the human proteome to reveal possible off-target proteins causing adverse side effects, early in the drug development process and to use that information to structurally optimize the drug candidates."

About caprotec bioanalytics

caprotec bioanalytics GmbH is headquartered in Berlin, Germany with a US subsidiary in Burlington, MA. The company was founded in 2006 by CEO Prof. Dr. Hubert Koster, prominent scientist and entrepreneur, who is also the founder of Sequenom, co-founder of US company Milligen/Biosearch and founder of Biosyntech GmbH, the first biotechnology company in Germany. caprotec focuses on the commercialization of its proprietary Capture Compound Mass Spectrometry (CCMS) technology in the areas of functional proteomics, drug development and development of biomarkers. The company holds a vast portfolio of 41 international patents of which are 21 already granted.

About LBBW Venture Capital GmbH

LBBW Venture is a subsidiary of Landesbank Baden-Wurttemberg and invests in Life Science, IT and industrial technology in Germany since more than ten years. Portfolio companies in the Life Science sector are Cellzome, Curacyte Pharmaceuticals, Phenex Pharmaceuticals, mtm laboratories and several fund in fund investments. Most recently the portfolio companies ProbioGen and Sloning were successfully sold.


'/>"/>
SOURCE caprotec bioanalytics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. caprotec bioanalytics GmbH Appoints Prof. Dr. Rainer Metternich as Managing Director, Chief Business Officer and Chief Operating Officer
2. Blocking carbon dioxide fixation in bacteria increases biofuel production
3. World TB Day Donation Campaign Increases Access to Improved TB Tests in Resource-Limited Settings
4. Quest Diagnostics Increases Share Repurchase Authority By $250 Million
5. First Duplex Test for Parvovirus B19 and Hepatitis A Virus Increases Safety of Human Plasma and Plasma Products
6. Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies
7. ThermoGenesis Announces Sale of BioArchive Systems In Asia as Company Increases Presence In Key Market
8. Caliper Enhances Strategic Focus and Increases Growth Capital with Sale of Product Lines to Biotage
9. Australia Substantially Increases Research Collaboration with China, According to Thomson Reuters Study
10. Updated Abbott Statement: To Help Respond to Growing Health Crisis, Abbott Increases Aid to $2.5 Million for Haiti Relief and Recovery Efforts
11. Zeus Increases Its Presence in Aerospace Industry with AS9100 Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... , ... Disappearing forests and increased emissions are the main causes of the ... Especially those living in larger cities are affected by air pollution related diseases. , ... pollution-affected countries globally - decided to take action. , “I knew I had to ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive ... a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... California (PRWEB) , ... October 10, 2017 , ... Dr. ... speaking at his local San Diego Rotary Club. The event entitled ... Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by ...
Breaking Biology Technology:
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/30/2017)... -- The research team of The Hong Kong Polytechnic ... by adopting ground breaking 3D fingerprint minutiae recovery and matching technology, ... accuracy for use in identification, crime investigation, immigration control, security of ... ... A research team led by Dr ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
Breaking Biology News(10 mins):